Previous studies have shown that a subpopulation of the catecholamine-degrading enzymes monoamine oxidase (MAO) A and B holds a previously unknown regulatory site, the I 2 -imidazoline binding site (I 2 BS). In the present work, we characterized the isoforms of monoamine oxidases expressed in the rabbit renal proximal tubule, defined their relationship with I 2 BS, and investigated the ability of I 2 BS ligands to inhibit enzyme activity in intact cells. Two findings indicate that MAO-B is the predominant isoform expressed in the renal proximal tubule cells: 1) Western blot performed with an anti-MAO-A/MAO-B polyclonal antiserum revealed a single 55-kDa band corresponding to MAO-B; 2) enzyme assays showed an elevated MAO-B activity ([ MAO (EC 1.4.3.4) are mitochondrial enzymes involved in the oxidative deamination of neurotransmitters (i.e., norepinephrine, dopamine, and 5-HT) and exogenous amines (1). They participate in the control of cell functions through different mechanisms, including the regulation of neurotransmitter concentrations, the generation of oxygen reactive species, and the production of active metabolites. Two isoforms of the enzyme, MAO-A and MAO-B, have been identified. They are encoded by two distinct genes with an intron/exon structure (2, 3) and can be differentiated based on the substrate specificity and the inhibition by synthetic compounds (1, 4). MAO-A preferentially metabolizes 5-HT and is inhibited by clorgyline and RO 41-1049; MAO-B has a greater affinity for phenylethylamine and is selectively inhibited by deprenyl and RO 19 -6327. Both isoforms display similar affinities for dopamine, adrenaline, and noradrenaline (1, 5). Several studies have shown that each of the two isoforms is specifically altered in different pathologies: a decrease in MAO-A activity is associated with aggressive behavior in humans and transgenic mice (6, 7); on the other hand, MAO-B seems to play a critical role in the development and/or maintenance of some neurodegenerative disorders, such as the Parkinson's and Alzheimer's diseases (8 -11).
MAO (EC 1.4.3.4) are mitochondrial enzymes involved in the oxidative deamination of neurotransmitters (i.e., norepinephrine, dopamine, and 5-HT) and exogenous amines (1) . They participate in the control of cell functions through different mechanisms, including the regulation of neurotransmitter concentrations, the generation of oxygen reactive species, and the production of active metabolites. Two isoforms of the enzyme, MAO-A and MAO-B, have been identified. They are encoded by two distinct genes with an intron/exon structure (2, 3) and can be differentiated based on the substrate specificity and the inhibition by synthetic compounds (1, 4) . MAO-A preferentially metabolizes 5-HT and is inhibited by clorgyline and RO 41-1049; MAO-B has a greater affinity for phenylethylamine and is selectively inhibited by deprenyl and RO 19 -6327. Both isoforms display similar affinities for dopamine, adrenaline, and noradrenaline (1, 5) . Several studies have shown that each of the two isoforms is specifically altered in different pathologies: a decrease in MAO-A activity is associated with aggressive behavior in humans and transgenic mice (6, 7) ; on the other hand, MAO-B seems to play a critical role in the development and/or maintenance of some neurodegenerative disorders, such as the Parkinson's and Alzheimer's diseases (8 -11) .
Recently, we identified a previously unknown MAO regulatory site, I 2 BS, and showed its localization on both MAO-A and MAO-B (12, 13) . This binding site, the major characteristic of which is its high affinity for a series of imidazoline and guanidinium compounds, is distinct from the catalytic site (12) , the FAD prosthetic group (14) and the binding sites of classical MAO inhibitors (13, 15) . The identification of I 2 BS has provided evidence for the existence of a heterogeneous population of MAO-B. Indeed, photoaffinity labeling using [
125 I]AZIPI showed that I 2 BS could be identified on human liver but not on human platelet MAO-B (13). This finding is particularly interesting; it suggests that I 2 BS may represent the first target for the identification and the pharmacological control of a specific subpopulation of the enzyme. The functional relevance of I 2 BS has been supported by enzyme assays, which show that, in membrane preparations from rabbit kidney (12) , rat liver, and adipocytes (15) , MAO activity is inhibited by selective I 2 BS ligands in a noncompetitive manner. Although these results suggest that I 2 BS ligands may represent a new class of MAO inhibitors, it was still necessary to show that these molecules are able to diffuse into the cells to interact with mitochondrial MAO. Among the organs, the kidney displays one of the highest MAO activities. Both MAO-A and MAO-B have been identified in the cortex and medulla of rat and human kidney: MAO-B is predominant in the renal cortex, whereas MAO-A seems to be equally expressed in the cortex and the medulla (16) .
Three findings suggest that MAO may have a particularly important role in the renal proximal tubule: 1) the MAO substrates norepinephrine, 5-HT, and dopamine play a critical role in renal proximal tubule sodium reabsorption (17) (18) (19) ; 2) dopamine can be directly produced and secreted by the proximal tubule (20, 21) ; and 3) dopamine release and metabolism by rat renal cortical slices depend, in part, on the degree of MAO activity (22) .
In the present work, we characterized the isoforms of MAO expressed in the rabbit renal proximal tubule, defined their relationship with I 2 BS, and investigated the ability of I 2 BS ligands to inhibit enzyme activity in intact cells.
Our results show that MAO-B is the predominant isoform expressed in rabbit proximal tubule cells. Similar to MAO-B in liver, this isoform possesses I 2 BS accessible to the ligands. In intact cells, I 2 BS ligands diffuse into the cells and bind to and inhibit MAO-B activity. The interaction of I 2 BS ligands with MAO-B in intact cells further supports the interest in this class of molecules as potential MAO inhibitors in vivo.
Materials and Methods
Rabbit proximal tubule cell preparation. Rabbit kidney proximal tubule cells were isolated from New Zealand White rabbits using the technique previously described by Poujeol and Vandewalle (23) . For each experiment, one adult male rabbit (CPA, Olivet, France) was killed by intravenous injection of 5 ml of pentobarbital sodium (Leo, St. Quentin/Yveline, France) and 2500 units of heparin (Sanofi, Libourne, France). Then, kidneys were removed rapidly and perfused with RPMI-1640 medium (GIBCO BRL, Cergy Pontoise, France) devoid of sodium bicarbonate and L-glutamine and buffered with 25 mM HEPES at pH 7.4. After decapsulation, the superficial cortex of the kidney was sliced, rinsed, and, finally, homogenized in a Dounce homogenizer (pestel A) (Polylabo, Strasbourg, France). The homogenate was successively filtered through 100-, 40-, and 20 M nylon meshes (Technofix, Arcueil, France) and centrifuged at 245 ϫ g for 10 min. The resulting supernatant was discarded, and the pellet was resuspended in RPMI-1640 medium and centrifuged twice, once at 44 ϫ g for 15 sec and once at 245 ϫ g for 10 min. After the second centrifugation, the pellet containing the cells was resuspended in buffer A (10 mM Tris⅐HCl, 140 mM NaCl, 5 mM KCl and 5 mM glucose, pH 7.4). This procedure yielded from 2 ϫ 10 8 to 3 ϫ 10 8 cells. The total number of cells was estimated by microscopic observation, and cells were used at a final concentration of 4 ϫ 10 6 cells/ml in buffer A.
Mitochondrial membrane preparations from renal cortex.
Mitochondrial membranes were obtained as previously reported (24) . Rabbit renal cortices were washed in ice-cold buffer B (250 mM sucrose, 0.1 mM phenylmethylsulfonyl fluoride, 2 mM Tris-HEPES, pH 7.4) and disrupted in a Turrax homogenizer (Jankel & Kunkel KG, Staufen, UK). After 10 additional passes in a Dounce homogenizer, the homogenate was filtered through two layers of cheesecloth mesh and centrifuged at 500 ϫ g for 10 min at 4°. The resulting pellet was discarded, and the supernatant was centrifuged at 16,000 ϫ g for 30 min at 4°. The supernatant and the white upper pellet of this centrifugation were eliminated. The intermediate pellet (mitochondrial fraction) was washed twice in ice-cold buffer containing 50 mM Tris⅐HCl, 2 mM EGTA, pH 7.4, and protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10 g/ml bacitracin, and 2 g/ml soybean trypsin inhibitor) and stored at Ϫ80°. Ϫ6 M rauwolscine to mask ␣ 2 -adrenoceptors. Incubation was stopped by adding 5 ml of ice-cold buffer C (10 mM Tris⅐HCl and 140 mM NaCl, pH 7.4). Then, samples were filtered through glass fiber filters (Whatman, Maidstone, UK), washed with 2 ϫ 5 ml of buffer C, and placed in 5 ml of Ready-Safe scintillation fluid (Beckman Instruments, Palo Alto, CA). Radioactivity was counted in a liquid scintillation spectrometer (Model Tri-Carb 4000; Packard, Meriden, CT) at 56% efficiency.
Nonspecific binding, which represents 30-35% of the total binding at radioligands concentrations around the dissociation constant (K d ) was defined in the presence of 10 M cirazoline.
For radioligand binding assay in the supernatant of digitonintreated cells, the incubation was stopped by precipitation with 1 mg/ml bovine ␥ globulin (in 100 mM Tris⅐HCl, pH 7.4)/25% polyethylene glycol, followed by vacuum filtration over glass fiber filters (GF/B; Whatman). The filters were then washed with 2 ϫ 4 ml of 8% polyethylene glycol in 50 mM Tris⅐HCl, pH 7.4 (24) .
MAO activity. Renal cortical membranes or isolated cells (100-200 g) were incubated at 37°for 20 min for a final volume of 250 l of sodium phosphate buffer, 50 mM, pH 7.5, with the required concentrations of [ or deprenyl (10 Ϫ7 M) was used to define specific MAO-A or MAO-B activity, respectively. Inhibition curves in membrane preparations from rabbit renal cortex showed that these clorgyline and deprenyl concentrations selectively inhibited MAO-A and MAO-B activities (data not shown). The reaction was ended by adding 1 ml of HCl at 4°. The reaction product was extracted by adding 2 ml of ethyl acetate/toluene (v/v), and the radioactivity contained in the organic phase was counted in a liquid scintillation spectrometer at 97% efficiency.
Cell viability. Cell viability was determined by using the trypan blue exclusion test and the measure of the LDH released from the cells. LDH activity was determined by using an Enzyline LDH Standardisé 50 assay kit (Bio Mérieux, Charbonnières les Bains, France).
Photoaffinity labeling. The cirazoline derivative AZIPI was iodinated and converted to the photolabile azide ([ 125 I]AZIPI) for use as a photoaffinity adduct as described previously by Lanier et al. (25) . Rabbit renal proximal tubule cells were first sonicated and then incubated in reduced light with 1-2 nM [
125 I]AZIPI for 30 min at 24°, chilled on ice, and diluted 10-fold with a buffer containing 50 mM Tris⅐HCl, pH 7.4, 2 mM EGTA, 1 mM MgCl 2 , and 2 mM dithiothreitol. Samples were immediately photolyzed at 4°for 5 min in a photolysis chamber (320 nm). Photolabeled membranes were centrifuged, solubilized in sample buffer (60 mM Tris⅐HCl, pH 6.8, 10% glycerol, 2% SDS, 1% 2-␤-mercaptoethanol, and 0.05% bromphenol blue) at 100°f or 5 min, and, finally, subjected to 9% SDS-PAGE. After electrophoresis, the gels were dried under a vacuum and analyzed using a 445 SI PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Immunoblot. Sonicated proximal tubule cells and renal cortex membranes were solubilized in the SDS-PAGE sample buffer. Two hundred micrograms of protein per well were loaded onto 9% SDS-PAGE gels. Resolved proteins were electrophoretically transferred to polyvinylidene difluoride membranes by semidry electroblotting (Trans-Blot SD; BioRad, Richmond, CA), and blots were blocked with 5% nonfat dry milk in wash buffer (phosphate-buffered saline, pH 7.5, and 0.1% Tween 20), washed twice, and incubated for 1 hr at room temperature with rabbit polyclonal antisera to MAO-A and MAO-B. The polyclonal antisera were obtained from rabbits immunized with the peptide TNGGQERKFVGGSGQ, which corresponds to amino acids 210-227 in MAO-A and 202-217 in MAO-B. The specificity of the antibody was determined by peptide competition in heterologous expression systems and various tissues. After being washed, blots were incubated with peroxidase-labeled anti-rabbit IgG for 40 min. Bound antibodies were detected using enhanced chemiluminescence ( 
Results
In a first series of experiments, the expression of MAO was investigated in the rabbit renal cortex. MAO isoforms were identified by Western blot analysis and enzyme assays. Western blot analyses were performed using an antiserum obtained for rabbits immunized with a peptide common to MAO-A and MAO-B and conserved in humans, rats, and calves. The specificity of this antiserum was defined by showing that 1) the apparent molecular masses of the two bands detected by this antiserum are identical to those of MAO-A and MAO-B, as determined by SDS-PAGE (approximately 60 and 55 kDa, respectively) (26); 2) in various tissues, the identification of the MAO isoforms by Western blot analysis or enzyme assays supplied identical results (data not shown); and 3) immunolabeling was prevented by the preincubation of the antiserum with the synthetic peptide. As shown in Fig.  1A , Western blot analysis of membrane preparations from renal cortex revealed two peptides with the apparent molecular weights expected for the two isoforms of MAO. The identification of these two peptides with MAO-A and MAO-B was confirmed by enzyme assays. Indeed, both (Fig. 1B) . These data show that both MAO-A and MAO-B are expressed in rabbit renal cortex.
Next, we investigated whether the MAO activity in the renal cortex could be related to the localization of the enzyme in the proximal tubule. With this aim, Western blot analysis and enzyme assays were performed on isolated proximal tubule cells. Before enzyme assay, isolated cells were disrupted by sonication to make MAO-A and MAO-B fully accessible to their substrates. In contrast to the results obtained in renal cortex, only MAO-B could be detected by immunoblot in isolated proximal tubule cells (Fig. 1A) . Enzyme assays showed that the MAO-B substrate [ (Fig. 2) . These results indicate that MAO-B is the predominant MAO isoform expressed in the renal proximal tubule.
It has been previously shown that the accessibility of MAO-B I 2 BS to their ligands may depend on the tissue localization. Indeed, the use of the photoaffinity I 2 BS ligand [ 125 I]AZIPI allowed the photolabeling of human liver but not human platelet MAO-B (13). To verify whether renal proxi- (Fig. 4) . Scatchard plot of saturation isotherms (Fig. 4, inset) Ϫ7 or 10 Ϫ5 M cirazoline. After SDS-PAGE, the gels were dried under a vacuum and analyzed using a Molecular Dynamics PhosphorImager. Arrow, migration of photolabeled protein with a molecular mass of 55 kDa. Downloaded from min). Then, intracellular I 2 BS were made fully accessible to the radioligand by cell permeabilization using the detergent digitonin. Finally, membrane-bound [ 3 H]idazoxan was separated from the free radioligand by filtration through glass fiber filters.
Cell release of the cytosolic enzyme LDH was used as an index of cell permeabilization. LDH activity was not detectable in the supernatant of isolated cells maintained at 4°for up to 120 min (data not shown). As shown in Fig. 5A , cell treatment with digitonin induced the release of LDH and, at the same time, decreased [ 3 H]idazoxan binding. The effect of digitonin was dose-dependent and reached the maximum at a concentration of 0.01%. [ 3 H]Idazoxan binding and LDH release were positively correlated ( p Ͻ 0.001) (Fig. 5B) . Two observations indicated that the decrease in [ 3 H]idazoxan binding was not related to the solubilization of membranebound I 2 BS: 1) experiments performed in membrane preparations showed that solubilization of I 2 BS required digitonin concentrations higher than 0.2% (24) and 2) no binding activity was detected in the cell supernatant as defined using the filtration protocol for soluble proteins. As shown in Fig. 6 , the residual [ 3 H]idazoxan binding found after cell treatment with 0.01% digitonin was similar to that determined in isolated cells sonicated before binding assay. These data indicate that, in intact cells, intracellular I 2 BS are fully occupied by specific imidazoline and guanidinium ligands.
These results were confirmed by the experiments on the inhibition of MAO activity by imidazoline and guanidinium drugs performed in intact cells. Cells were incubated for 20 min with various imidazoline and guanidinium derivatives before the addition of the MAO substrate [ 14 C]tyramine. As shown in Fig. 7 , MAO activity was inhibited by the I 2 BS ligand cirazoline, guanabenz, and idazoxan and was not affected by the I 2 BS ligands clonidine and rilmenidine. This order of potency is identical to that found in sonicated cells (data not shown) and corresponds to the pharmacological profile of I 2 BS. Thus, both radioligand binding studies and enzyme assays clearly showed that, in intact cells, I 2 BS ligands can bind to and inhibit MAO activity. 
MAO, I 2 -BS, and Rabbit Kidney Discussion
Noradrenaline and dopamine, two neurotransmitters metabolized by MAO, play a critical role in the regulation of sodium handling in the renal proximal tubule. In this segment of the nephron, these two catecholamines induce opposite effects: noradrenaline increases tubular sodium reabsorption by the activation of the Na ϩ /H ϩ antiporter (27) , whereas dopamine decreases tubular sodium reabsorption by regulating different transport systems, including the Na ϩ /H ϩ antiporter, the Na ϩ -K ϩ pump, and the Na ϩ /Pi cotransport (28, 29) . Although noradrenaline is released by renal sympathetic nervous endings, most dopamine is directly synthesized by the renal proximal tubule cells. Indeed, it has been shown that the dopamine precursor L-dihydroxyphenylalanine is transported into the cells and is converted into dopamine by aromatic-L-amino acid decarboxylase (30) . Dopamine is then secreted by the renal proximal tubule cells and acts as an autocrine/paracrine factor.
Recent studies have shown the extraneuronal location of both MAO-A and MAO-B in the renal tissues (31) and their involvement in the regulation of renal dopamine content. Indeed, experiments performed in rat renal cortical slices showed that inhibition of MAO increases the dopamine release and decreases the concentration of the dopamine metabolites dihydrophenylacetic acid and homovanillic acid (32) . The study of the effect of selective MAO inhibitors on dopamine accumulation suggests that, at least in the rat, both MAO-A and MAO-B are responsible for degradation of renal dopamine. The identification of the MAO isoforms expressed in the proximal tubule represents a critical step in the comprehension of their respective roles in the metabolism of renal dopamine.
In the present study, we showed that both MAO-A and MAO-B are expressed in the rabbit renal cortex. In contrast, three major findings indicate that MAO-B is the predominant MAO isoform expressed in the rabbit renal proximal tubule: 1) Western blot analysis revealed a single 55-kDa band corresponding to MAO-B; 2) enzyme assays showed an elevated MAO-B activity, whereas MAO-A activity was only detectable; and 3) photoaffinity labeling with the I 2 BS ligand [ 125 I]AZIPI revealed only MAO-B in isolated proximal tubule cells, whereas both MAO isoforms were detected in the rabbit renal cortex (26) . Such localization of MAO-B does not seem to be unique to the rabbit, as we have recently found elevated MAO-B activity in rat renal proximal tubule. 1 These results suggest that MAO-B may be the MAO isoform that plays a major role in the degradation of the dopamine produced by renal proximal tubule cells.
Photoaffinity labeling experiments show that rabbit renal proximal tubule MAO-B carries the I 2 BS. Radioligand binding data performed in membrane preparations from isolated cells using [ 3 H]Ro 19 -6327, a MAO-B-specific ligand, showed a density of MAO-B molecules 5-to 6-fold higher than that of I 2 BS (data not shown). This different stoichiometry is in agreement with previous results (33) and confirms that I 2 BS are localized on a subpopulation of the enzyme. Radioligand binding studies and enzyme assays clearly showed that, in intact renal proximal tubule cells, I 2 BS ligands reach the cell cytosol and interact with MAO-B. The following observations suggest that the entrance of I 2 BS ligands into the cells does not require specific transport systems: 1) radioligand binding experiments were performed at 4°to minimize the activity of the energy-dependent transport systems as well as the internalization of ligand-receptor complexes; 2) the entry of I 2 BS ligands into the cells did not require specific co-transported factors. Indeed, [ 3 H]idazoxan binding to intracellular binding was maximal using an incubation medium containing only Tris and the nondiffusible cation substitute N-methyl-D-glucamine (7); 3) as previously reported in mitochondrial membrane preparations, Scatchard plot of saturation binding data was linear, which indicates that [ 3 H]idazoxan interacts with a single population of binding sites. Thus, I 2 BS ligands seem to freely cross the plasma membrane after a gradient concentration. This possibility is supported by the fact that these ligands are strongly lipophilic, presenting an octanol/water coefficient partition higher than unit.
As shown by the enzyme assay, the interaction of I 2 BS ligands with MAO induced a dose-dependent inhibition of the enzyme activity. Comparison of these results with those obtained from radioligand studies show that inhibition constants of imidazoline derivatives were lower for [
3 H]idazoxan binding to I 2 BS than for MAO activities. In previous studies (12), we made the hypothesis that, in membrane preparations, this discrepancy could be related to the absence of an unknown regulatory cell factor, which is necessary to increase the potency of imidazoline ligands for the inhibition of enzyme activity. The fact that we have observed the same discrepancy in an intact cell system makes this hypothesis unlikely. At present, the relationship between the occupancy of I 2 BS and the inhibition of the enzyme activity needs further investigation. It is possible that MAO inhibition by the imidazoline ligands is related to the interaction with a low affinity site localized on the entire population of MAO. The characterization of the functional activity of the high affinity I 2 BS, which is localized on a subpopulation of the enzyme, requires the identification and the isolation of the MAO subtype. Nevertheless, the demonstration that imidazoline ligands inhibit MAO activity in intact cells reveals a novel mechanism of action of this class of drugs and may have relevance in the therapy of diseases in which MAO function is altered.
Our findings may have particular relevance to the field of hypertension. Indeed, it has been shown that, in a subpopulation of hypertensive patients (34) and in rat models of essential hypertension (35) , the renal dopamine content was decreased with respect to the control subjects. In addition, modification of MAO activity has been reported in a rat model of spontaneous hypertension (5) .
The demonstration that MAO-B is the predominant isoform expressed in the proximal tubule is a critical step in defining its role in the control of tubular function and in the development of hypertension. The fact that I 2 BS ligands interact with MAO-B in intact renal proximal tubule cells suggests a potential role for these compounds in the pharmacological control of MAO activity in vivo.
